Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BRUKER CORPBRKR · Entity 3609 | Director | May 15, 2026 | May 19, 2026 |
| NEOGEN CORPNEOG · Entity 4338 | Director | October 23, 2025 | October 27, 2025 |
| T2 Biosystems, Inc.TTOO · Entity 11728 | Director | September 15, 2023 | October 11, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BRUKER CORP
Report date May 15, 2026 · Filed May 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,886 |
Reported balance
After 2026-05-15 transaction · row 1
1 source rowRow 1 · 2026-05-15 · Grant · Acquired 2,886 · Balance 2,886 F1: This grant is represented by Restricted Stock Units (RSU) and will vest in one installment on May 15, 2027. On the vesting date, each RSU will automatically convert into a similar number of shares of Common Stock. |
Filing footnotes · ownership attribution and instrument terms
F1: This grant is represented by Restricted Stock Units (RSU) and will vest in one installment on May 15, 2027. On the vesting date, each RSU will automatically convert into a similar number of shares of Common Stock.
NEOGEN CORP
Report date October 23, 2025 · Filed October 27, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 19,769 |
Reported balance
After 2025-10-23 transaction · row 1
1 source rowRow 1 · 2025-10-23 · Grant · Acquired 19,769 · Balance 19,769 F1: Options and RSUs vest in equal annual installments on each of the first three anniversary dates of the grants |
| Common Stock (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.07 · Expires 2035-10-23 | Direct | 50,814 |
Reported balance
After 2025-10-23 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-10-23 · Grant · Acquired 50,814 · Balance 50,814 F1: Options and RSUs vest in equal annual installments on each of the first three anniversary dates of the grants |
Filing footnotes · ownership attribution and instrument terms
F1: Options and RSUs vest in equal annual installments on each of the first three anniversary dates of the grants
T2 Biosystems, Inc.
Report date September 15, 2023 · Filed October 11, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,322 |
Reported balance
After 2023-09-15 transaction · row 1
1 source rowRow 1 · 2023-09-15 · Exercise / conversion · Acquired 2,300 · Balance 7,322 F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-09-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-09-15 · Exercise / conversion · Disposed 2,300 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2: On October 11, 2022, the reporting person was granted 2,300 restricted stock units that vested on the earlier of (i) October 11, 2023, and (ii) the date of the next annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F2: On October 11, 2022, the reporting person was granted 2,300 restricted stock units that vested on the earlier of (i) October 11, 2023, and (ii) the date of the next annual meeting of stockholders.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 15, 2026 Filed May 19, 2026 21:30 UTC | BRUKER CORP BRKR · Entity 3609 | GrantCommon Stock | 2,886 | $0.00 | $0.00 |
DisclosureSEC source: 0001815490-26-000004 · form4-05192026_050501.xml · nonDerivative · entry 1 Bernard Thierry · CIK 0001815490 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,886 F1 · shares: This grant is represented by Restricted Stock Units (RSU) and will vest in one installment on May 15, 2027. On the vesting date, each RSU will automatically convert into a similar number of shares of Common Stock. Read SEC document |
| October 23, 2025 Filed Oct 27, 2025 19:40 UTC | NEOGEN CORP NEOG · Entity 4338 | GrantCommon Stock (Right to Buy) · Derivative | 50,814 | $0.00 Strike: $6.07 | $0.00 |
DisclosureSEC source: 0000711377-25-000050 · primary_doc.xml · derivative · entry 2 Bernard Thierry · CIK 0001815490 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,814 Underlying: Common Stock · 50,814 shares Expires 2035-10-23 F1 · derivative.exercise_date: Options and RSUs vest in equal annual installments on each of the first three anniversary dates of the grants Read SEC document |
| October 23, 2025 Filed Oct 27, 2025 19:40 UTC | NEOGEN CORP NEOG · Entity 4338 | GrantCommon Stock | 19,769 | $6.07 | $119,997.83 |
DisclosureSEC source: 0000711377-25-000050 · primary_doc.xml · nonDerivative · entry 1 Bernard Thierry · CIK 0001815490 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,769 F1 · shares: Options and RSUs vest in equal annual installments on each of the first three anniversary dates of the grants Read SEC document |
| November 01, 2024 Filed Nov 5, 2024 18:07 UTC | NEOGEN CORP NEOG · Entity 4338 | GrantCommon Stock (Right to Buy) · Derivative | 17,207 | $0.00 Strike: $14.44 | $0.00 |
DisclosureSEC source: 0000711377-24-000058 · primary_doc.xml · derivative · entry 2 Bernard Thierry · CIK 0001815490 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,207 Underlying: Common Stock · 17,207 shares Expires 2031-11-01 F1 · derivative.exercise_date: Options and RSUs vest in equal annual installments on each of the first three anniversary dates of the grants Read SEC document |
| November 01, 2024 Filed Nov 5, 2024 18:07 UTC | NEOGEN CORP NEOG · Entity 4338 | GrantRestricted Stock Units | 5,620 | $14.44 | $81,152.80 |
DisclosureSEC source: 0000711377-24-000058 · primary_doc.xml · nonDerivative · entry 1 Bernard Thierry · CIK 0001815490 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,620 F1 · shares: Options and RSUs vest in equal annual installments on each of the first three anniversary dates of the grants Read SEC document |
| September 15, 2023 Filed Oct 11, 2023 21:00 UTC | T2 Biosystems, Inc. TTOO · Entity 11728 | Exercise / conversionRestricted Stock Units · Derivative | 2,300 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-052930 · ownership.xml · derivative · entry 2 Bernard Thierry · CIK 0001815490 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,300 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: On October 11, 2022, the reporting person was granted 2,300 restricted stock units that vested on the earlier of (i) October 11, 2023, and (ii) the date of the next annual meeting of stockholders. F2 · derivative.expiration_date: On October 11, 2022, the reporting person was granted 2,300 restricted stock units that vested on the earlier of (i) October 11, 2023, and (ii) the date of the next annual meeting of stockholders. Read SEC document |
| September 15, 2023 Filed Oct 11, 2023 21:00 UTC | T2 Biosystems, Inc. TTOO · Entity 11728 | Exercise / conversionCommon Stock | 2,300 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-23-052930 · ownership.xml · nonDerivative · entry 1 Bernard Thierry · CIK 0001815490 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,322 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| August 06, 2023 Filed Aug 16, 2023 20:01 UTC | T2 Biosystems, Inc. TTOO · Entity 11728 | Exercise / conversionRestricted Stock Units · Derivative | 454 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-043001 · ownership.xml · derivative · entry 4 Bernard Thierry · CIK 0001815490 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 454 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: On August 6, 2020 the reporting person was granted 1,363 RSU's that vest in three equal annual installments beginning on August 6, 2021. F3 · derivative.expiration_date: On August 6, 2020 the reporting person was granted 1,363 RSU's that vest in three equal annual installments beginning on August 6, 2021. Read SEC document |
| August 06, 2023 Filed Aug 16, 2023 20:01 UTC | T2 Biosystems, Inc. TTOO · Entity 11728 | Exercise / conversionCommon Stock | 454 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-23-043001 · ownership.xml · nonDerivative · entry 2 Bernard Thierry · CIK 0001815490 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,022 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| January 01, 2023 Filed Aug 16, 2023 20:01 UTC | T2 Biosystems, Inc. TTOO · Entity 11728 | Exercise / conversionRestricted Stock Units · Derivative | 1,550 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-043001 · ownership.xml · derivative · entry 3 Bernard Thierry · CIK 0001815490 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,550 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: On January 1, 2022 the reporting person was granted 1,550 RSU's that vested in one installment on January 1, 2023. F2 · derivative.expiration_date: On January 1, 2022 the reporting person was granted 1,550 RSU's that vested in one installment on January 1, 2023. Read SEC document |
| January 01, 2023 Filed Aug 16, 2023 20:01 UTC | T2 Biosystems, Inc. TTOO · Entity 11728 | Exercise / conversionCommon Stock | 1,550 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-23-043001 · ownership.xml · nonDerivative · entry 1 Bernard Thierry · CIK 0001815490 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,568 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| October 11, 2022 Filed Oct 13, 2022 20:00 UTC | T2 Biosystems, Inc. TTOO · Entity 11728 | GrantRestricted Stock Units · Derivative | 115,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-033553 · doc4.xml · derivative · entry 1 Bernard Thierry · CIK 0001815490 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,000 Underlying: Common Stock · 115,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F2 · derivative.exercise_date: The restricted stock units vest in one installment on the earlier of (i) October 11, 2023 and (ii) the date of the next annual meeting of stockholders. F2 · derivative.expiration_date: The restricted stock units vest in one installment on the earlier of (i) October 11, 2023 and (ii) the date of the next annual meeting of stockholders. Read SEC document |
| August 06, 2022 Filed Aug 9, 2022 20:00 UTC | T2 Biosystems, Inc. TTOO · Entity 11728 | Exercise / conversionRestricted Stock Units · Derivative | 22,727 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-028079 · doc4.xml · derivative · entry 2 Bernard Thierry · CIK 0001815490 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,727 Underlying: Common Stock · 22,727 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: On August 6, 2020 the reporting person was granted 68,181 RSU's that vest in three equal annual installments beginning on August 6, 2021. F2 · derivative.expiration_date: On August 6, 2020 the reporting person was granted 68,181 RSU's that vest in three equal annual installments beginning on August 6, 2021. Read SEC document |
| August 06, 2022 Filed Aug 9, 2022 20:00 UTC | T2 Biosystems, Inc. TTOO · Entity 11728 | Exercise / conversionCommon Stock | 22,727 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-028079 · doc4.xml · nonDerivative · entry 1 Bernard Thierry · CIK 0001815490 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,936 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| June 25, 2022 Filed Jun 28, 2022 21:27 UTC | T2 Biosystems, Inc. TTOO · Entity 11728 | Exercise / conversionRestricted Stock Units · Derivative | 73,224 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-024425 · doc4.xml · derivative · entry 2 Bernard Thierry · CIK 0001815490 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 73,224 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: On June 25, 2021, the reporting person was granted 73,224 restricted stock units that vested on the earlier of (i) June 25, 2022, and (ii) the date of the next annual meeting of stockholders. F2 · derivative.expiration_date: On June 25, 2021, the reporting person was granted 73,224 restricted stock units that vested on the earlier of (i) June 25, 2022, and (ii) the date of the next annual meeting of stockholders. Read SEC document |
| June 25, 2022 Filed Jun 28, 2022 21:27 UTC | T2 Biosystems, Inc. TTOO · Entity 11728 | Exercise / conversionCommon Stock | 73,224 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-024425 · doc4.xml · nonDerivative · entry 1 Bernard Thierry · CIK 0001815490 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,209 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| January 01, 2022 Filed Jan 4, 2022 20:59 UTC | T2 Biosystems, Inc. TTOO · Entity 11728 | GrantRestricted Stock Units · Derivative | 77,519 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-000459 · doc4.xml · derivative · entry 3 Bernard Thierry · CIK 0001815490 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,519 Underlying: Common Stock · 77,519 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The restricted stock units were granted in accordance with the Issuer's Non-Employee Director Compensation Plan and vest on January 1, 2023. F3 · derivative.expiration_date: The restricted stock units were granted in accordance with the Issuer's Non-Employee Director Compensation Plan and vest on January 1, 2023. Read SEC document |
| January 01, 2022 Filed Jan 4, 2022 20:59 UTC | T2 Biosystems, Inc. TTOO · Entity 11728 | Exercise / conversionRestricted Stock Units · Derivative | 32,258 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-000459 · doc4.xml · derivative · entry 2 Bernard Thierry · CIK 0001815490 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 32,258 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: On January 1, 2021 the reporting person was granted 32,258 restricted stock units that vested on January 1, 2022. F2 · derivative.expiration_date: On January 1, 2021 the reporting person was granted 32,258 restricted stock units that vested on January 1, 2022. Read SEC document |
| January 01, 2022 Filed Jan 4, 2022 20:59 UTC | T2 Biosystems, Inc. TTOO · Entity 11728 | Exercise / conversionCommon Stock | 32,258 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-000459 · doc4.xml · nonDerivative · entry 1 Bernard Thierry · CIK 0001815490 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,985 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| August 06, 2021 Filed Aug 9, 2021 20:00 UTC | T2 Biosystems, Inc. TTOO · Entity 11728 | Exercise / conversionRestricted Stock Units · Derivative | 22,727 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-032152 · doc4.xml · derivative · entry 2 Bernard Thierry · CIK 0001815490 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,454 Underlying: Common Stock · 22,727 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: On August 6, 2020 the reporting person was granted 68,181 RSU's that vest in three equal annual installments beginning on August 6, 2021. F2 · derivative.expiration_date: On August 6, 2020 the reporting person was granted 68,181 RSU's that vest in three equal annual installments beginning on August 6, 2021. Read SEC document |
| August 06, 2021 Filed Aug 9, 2021 20:00 UTC | T2 Biosystems, Inc. TTOO · Entity 11728 | Exercise / conversionCommon Stock | 22,727 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-032152 · doc4.xml · nonDerivative · entry 1 Bernard Thierry · CIK 0001815490 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,727 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| June 25, 2021 Filed Jun 29, 2021 19:00 UTC | T2 Biosystems, Inc. TTOO · Entity 11728 | GrantRestricted Stock Units · Derivative | 73,224 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-026535 · doc4.xml · derivative · entry 1 Bernard Thierry · CIK 0001815490 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,224 Underlying: Common Stock · 73,224 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F2 · derivative.exercise_date: The restricted stock units vest in one installment on the earlier of (i) June 25, 2022 and (ii) the date of the next annual meeting of stockholders. F2 · derivative.expiration_date: The restricted stock units vest in one installment on the earlier of (i) June 25, 2022 and (ii) the date of the next annual meeting of stockholders. Read SEC document |
| January 01, 2021 Filed Jan 5, 2021 20:10 UTC | T2 Biosystems, Inc. TTOO · Entity 11728 | GrantRestricted Stock Units · Derivative | 32,258 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-000326 · doc4.xml · derivative · entry 1 Bernard Thierry · CIK 0001815490 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,258 Underlying: Common Stock · 32,258 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted in accordance with the Issuer's Non-Employee Director Compensation Plan and vest on January 1, 2022. F2 · derivative.expiration_date: The restricted stock units were granted in accordance with the Issuer's Non-Employee Director Compensation Plan and vest on January 1, 2022. Read SEC document |
| August 06, 2020 Filed Aug 7, 2020 21:46 UTC | T2 Biosystems, Inc. TTOO · Entity 11728 | GrantRestricted Stock Units · Derivative | 68,181 | $0.00 | $0.00 |
DisclosureSEC source: 0000950123-20-007909 · doc4.xml · derivative · entry 1 Bernard Thierry · CIK 0001815490 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,181 Underlying: Common Stock · 68,181 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F2 · derivative.exercise_date: The restricted stock units vest and become exercisable in substantially equal installments on each of the first three anniversaries of the date of grant. F2 · derivative.expiration_date: The restricted stock units vest and become exercisable in substantially equal installments on each of the first three anniversaries of the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.